| Li, Li |
NCT05793892: Efficacy and Safety of Lidocaine and Tetracaine Cream for Facial Laser Aesthetics in Chinese Adults |
|
|
| Not yet recruiting | 3 | 286 | RoW | Lidocaine tetracaine cream, test drug:CU-30101, control drug:Pliaglis | Cutia Therapeutics（Wuxi）Co.,Ltd | Analgesia | 08/23 | 09/23 | | |
QWINT-2, NCT05362058: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time |
|
|
| Completed | 3 | 928 | Europe, Canada, Japan, US, RoW | Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec | Eli Lilly and Company | Diabetes, Type 2 Diabetes | 04/24 | 04/24 | | |
ATTAIN-1, NCT05869903: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities |
|
|
| Active, not recruiting | 3 | 3000 | Europe, Japan, US, RoW | Orforglipron, LY3502970, Placebo | Eli Lilly and Company | Obesity, Overweight, Overweight or Obesity | 09/25 | 09/27 | | |
| Recruiting | 3 | 2100 | Europe, Canada, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Obesity, Overweight, Knee Pain Chronic, Knee Osteoarthritis, Obstructive Sleep Apnea | 04/26 | 05/26 | | |
| Recruiting | 1/2 | 300 | RoW | JSKN003 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Advanced Solid Tumor | 12/24 | 12/25 | | |
NCT05068921: A Clinical Trial to Evaluate Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignancy |
|
|
| Recruiting | 1 | 40 | RoW | TQB2858 injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Cervical Cancer | 05/23 | 07/23 | | |
DEVIF-I, NCT06230822: Safety, Tolerability and Efficacy of VUM02 Injection in Treatment of Idiopathic Pulmonary Fibrosis (IPF) |
|
|
| Recruiting | 1 | 9 | RoW | VUM02 Injection, Human Umbilical Cord Tissue-derived Mesenchymal Stem Cells Injection | Wuhan Optics Valley Vcanbiopharma Co., Ltd. | Idiopathic Pulmonary Fibrosis | 01/25 | 12/26 | | |
OASIS, NCT06063317: A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 52 | US | CF33-CD19 IT, CF33-CD19 IV, Blinatumomab, Blincyto | Imugene Limited | Solid Tumor, Adult | 09/24 | 09/25 | | |
NCT05970497: A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 80 | US | KB707 | Krystal Biotech, Inc. | Cancer, Melanoma Stage III, Melanoma Stage IV, Cutaneous Melanoma, Osteosarcoma, Carcinoma, Squamous Cell, Carcinoma, Basal Cell | 07/26 | 07/26 | | |
| Li, Yan |
| Active, not recruiting | 3 | 1177 | Europe, Canada, Japan, US, RoW | Mirikizumab SC, LY3074828, Mirikizumab IV, Placebo SC | Eli Lilly and Company | Ulcerative Colitis | 11/21 | 12/24 | | |
|
|
| Active, not recruiting | 3 | 380 | Europe, Canada, Japan, US, RoW | Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo | Chinook Therapeutics U.S., Inc. | IgA Nephropathy, Immunoglobulin A Nephropathy | 09/23 | 12/26 | | |
NCT05433480: A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer |
|
|
| Active, not recruiting | 3 | 274 | RoW | BPI-16350, placebo, Fulvestrant | Betta Pharmaceuticals Co., Ltd. | Breast Cancer | 12/23 | 07/25 | | |
nAMD, NCT05461339: TAB014 Compared to Lucentis® in Patients With Neovascular Age-related Macular Degeneration |
|
|
| Recruiting | 3 | 488 | RoW | TAB014 Monoclonal Antibody Injection, TAB014, Ranibizumab Injection [Lucentis], Lucentis | TOT Biopharm Co., Ltd., Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | Neovascular Age-related Macular Degeneration | 03/24 | 03/24 | | |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
QWINT-2, NCT05362058: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time |
|
|
| Completed | 3 | 928 | Europe, Canada, Japan, US, RoW | Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec | Eli Lilly and Company | Diabetes, Type 2 Diabetes | 04/24 | 04/24 | | |
NCT04578613: ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL |
|
|
| Recruiting | 3 | 218 | RoW | ICP-022, Chlorambucil, Rituximab | Beijing InnoCare Pharma Tech Co., Ltd. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 12/24 | 06/25 | | |
| Active, not recruiting | 3 | 15374 | Europe, Canada, Japan, US, RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Obesity, Overweight | 10/27 | 10/27 | | |
NCT06083623: A Trial to Evaluate the Efficacy and Safety of TNM001 for the Prevention of Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus in Infants |
|
|
| Not yet recruiting | 2b | 2250 | RoW | TNM001, placebo | Zhuhai Trinomab Pharmaceutical Co., Ltd. | Respiratory Syncytial Virus Infections | 05/26 | 08/26 | | |
NCT05299697: A Study of TG103 Injection in Overweight or Obesity |
|
|
| Recruiting | 2 | 195 | RoW | TG103 15 mg, TG103 22.5 mg, Placebo | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Overweight or Obesity | 06/23 | 09/23 | | |
NCT06206720: A Study of Deuremidevir Hydrobromide for Suspension in Chinese Infants Hospitalized With RSV |
|
|
| Recruiting | 2 | 60 | RoW | Deuremidevir Hydrobromide for Suspension, VV116, Placebo, VV116 placebo | Vigonvita Life Sciences | Respiratory Syncytial Virus Infection | 09/24 | 12/24 | | |
NCT06481085: To Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus |
|
|
| Not yet recruiting | 2 | 318 | RoW | HDM1002 50 mg, HDM1002, HDM1002 100 mg, HDM1002 200 mg, HDM1002 400 mg, HDM1002 200 mg BID, Placebo, Matching placebo for group A to group E | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Type 2 Diabetes | 04/25 | 04/25 | | |
| Active, not recruiting | 2 | 103 | Europe, US, RoW | Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627 | Chinook Therapeutics U.S., Inc. | IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease, Diabetic Nephropathy Type 2, Immunoglobulin A Nephropathy | 07/24 | 07/26 | | |
NCT06106841: TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL) |
|
|
| Recruiting | 1/2 | 39 | RoW | 400mg of TQB3909 tablets, 600mg of TQB3909 tablets | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Mantle Cell Lymphoma | 12/24 | 12/24 | | |
NCT06052813: A Study of BN104 in the Treatment of Acute Leukemia |
|
|
| Recruiting | 1/2 | 90 | RoW | BN104 | BioNova Pharmaceuticals (Shanghai) LTD. | ALL, Adult, AML, Adult | 06/26 | 06/27 | | |
| Recruiting | 1 | 76 | RoW | HS-10380, Placebo | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Schizophrenia | 06/23 | 07/23 | | |
| Active, not recruiting | N/A | 482 | RoW | | Takeda | Multiple Myeloma, Neoplasms, Plasma Cell | 09/25 | 09/25 | | |
NCT04995159: Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVasâ„¢ BRS System |
|
|
| Not yet recruiting | N/A | 2150 | RoW | Single anti-platelet therapy, SAPT strategy, Dual anti-platelet therapy, DAPT strategy | Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Heart Disease | 01/26 | 01/28 | | |
| Li, Jie |
NCT04875169: Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis |
|
|
| Completed | 3 | 336 | Canada, RoW | Core Treatment Active Experimental: SHR0302 Dose#1, Core Treatment Active Experimental: SHR0302 Dose#2, Core Treatment Placebo Comparator: Placebo, Extension Treatment Active Experimental: SHR0302 Dose#1, Extension Treatment Active Experimental: SHR0302 Dose#2 | Reistone Biopharma Company Limited | Atopic Dermatitis | 08/22 | 05/23 | | |
NCT05525637: Safety and Efficacy Study of YZJ-1139 in Insomnia Disorder |
|
|
| Recruiting | 3 | 1041 | RoW | YZJ-1139 20mg, YZJ-1139 40mg, Placebo | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Insomnia Disorder | 12/24 | 12/24 | | |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
NCT06300177: D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure |
|
|
| Recruiting | 3 | 522 | RoW | D-1553 Tablet, Docetaxel injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non Small Cell Lung Cancer | 10/26 | 12/27 | | |
NCT06469879: A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients |
|
|
| Not yet recruiting | 3 | 358 | RoW | TQB2450+Anlotinib, TQB2450 placebo + Anlotinib placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Small Cell Lung Cancer Limited Stage | 09/26 | 09/26 | | |
NCT04983043: Efficacy and Safety of QiShen YiQi Dripping Pills in Chronic Heart Failure |
|
|
| Recruiting | 2 | 228 | RoW | Low dose QiShen YiQi Dripping Pills 3 bags, Low dose group, High dose QiShen YiQi Dripping Pills 3 bags, High dose group, QiShen YiQi Dripping Pills placebo 3 bags, Placebo group | Tasly Pharmaceutical Group Co., Ltd | Chronic Heart Failure With Reduced Ejection Fraction | 12/24 | 12/24 | | |
NCT06241781: Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer |
|
|
| Not yet recruiting | 2 | 64 | RoW | GT101 injection, Gemcitabine injection | Grit Biotechnology | Adult | 01/27 | 01/27 | | |
NCT05632861: HuHuangLianzonggan Capsule in Subjects With Nonalcoholic Steatohepatitis: a Phase 2 tRial(HHL-HEPAR) |
|
|
| Recruiting | 2 | 76 | RoW | HuHuangLianzonggan capsule, Experimental group, HuHuangLianzonggan capsule placebo, Placebo group | Tasly Pharmaceutical Group Co., Ltd | NASH | 12/24 | 12/24 | | |
NCT05959694: A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) . |
|
|
| Recruiting | 1/2 | 107 | RoW | TQB3909 tablet | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 12/25 | 06/26 | | |
EFLRWR, NCT05132218: Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer |
|
|
| Recruiting | N/A | 180 | RoW | Ensatinib, BD-EN-IV002 | Beijing Cancer Hospital, Betta Pharmaceuticals Co., Ltd. | ALK Positive, NSCLC Stage IIIB, NSCLC Stage IV | 10/22 | 10/24 | | |
| Chen, Jia Ching |
| Recruiting | 1/2 | 50 | RoW | CAR T-cell therapy | The First Affiliated Hospital of Soochow University, Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | Acute Lymphoblastic Leukemia With Failed Remission | 12/20 | 12/23 | | |
NCT05409482: A Real-world Study of Camrelizumab Combined With Apatinib Mesylate in Unresectable Hepatocellular Carcinoma |
|
|
| Recruiting | N/A | 300 | RoW | | Meng Chao Hepatobiliary Hospital of Fujian Medical University, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Hepatocellular Carcinoma | 03/26 | 03/26 | | |
| DU, XIAOBO |
FOCUS-C, NCT05334277: Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA |
|
|
| Recruiting | 2 | 280 | RoW | Furmonertinib, AST2818, Furmonertinib/Pemetrexed/Carboplatin, Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab | Sun Yat-sen University, Allist Pharmaceuticals, Inc., GeneCast Biotechnology Co., Ltd. | Non-small Cell Lung Cancer | 02/25 | 02/28 | | |
NCT05405439: To Evaluate the Efficacy of TQB3823 Combined With Abiraterone and Prednisone in Metastatic Castration-resistant Prostate Cancer Patientsprednisone Acetate Tablets in Patients With Metastatic Castration-resistant Prostate Cancer |
|
|
| Terminated | 1/2 | 39 | RoW | TQB3823 tablets, Abiraterone acetate tablets, prednisone acetate tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Metastatic Castration-resistant Prostate Cancer | 07/23 | 07/23 | | |
NCT05959694: A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) . |
|
|
| Recruiting | 1/2 | 107 | RoW | TQB3909 tablet | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 12/25 | 06/26 | | |
NCT06010901: A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer. |
|
|
| Recruiting | 1 | 75 | RoW | TQB2618 injection, Penpulimab injection, Anlotinib hydrochloride capsules | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Colorectal Cancer | 03/25 | 07/25 | | |
| Li, Hui |
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD) |
|
|
| Active, not recruiting | 4 | 8250 | RoW | Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy | Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases | 04/25 | 04/25 | | |
HER2CLIMB-02, NCT03975647: A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer |
|
|
| Recruiting | 3 | 565 | Europe, Canada, Japan, US, RoW | tucatinib, ONT-380, placebo, T-DM1, Kadcyla | Seagen Inc. | HER2-positive Breast Cancer | 06/23 | 10/27 | | |
|
|
NCT05433480: A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer |
|
|
| Active, not recruiting | 3 | 274 | RoW | BPI-16350, placebo, Fulvestrant | Betta Pharmaceuticals Co., Ltd. | Breast Cancer | 12/23 | 07/25 | | |
NCT05555706: Study of B013 and Nab-Paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer |
|
|
| Recruiting | 2/3 | 450 | RoW | B013+Nab-Paclitaxel | Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd | Triple Negative Breast Cancer (TNBC) | 12/24 | 12/26 | | |
NCT05292196: A Phase II Clinical Trial of TQC3721 Suspension for Inhalation |
|
|
| Recruiting | 2 | 460 | RoW | TQC3721 suspension for inhalation, TQC3721 suspension placebo for inhalation | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Obstructive Pulmonary Disease (COPD) | 01/24 | 05/24 | | |
NCT05987371: A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease. |
|
|
| Recruiting | 2 | 72 | RoW | TQC3721 suspension for inhalation, TQC3721 matching placebo for inhalation, Salbutamol sulfate inhalation aerosol | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Obstructive Pulmonary Disease | 01/24 | 03/24 | | |
NCT02698839: A Study to Evaluate the Efficacy and Safety of BuMA Supreme Drug Eluting Stent(DES) |
|
|
| Active, not recruiting | N/A | 539 | RoW | BuMA Supreme, BuMA™ | Sino Medical Sciences Technology Inc. | Coronary Artery Disease | 03/18 | 12/25 | | |
OPC, NCT02698852: A Study to Evaluate the Efficacy and Safety of BuMA Supreme Drug Eluting Stent(DES) |
|
|
| Active, not recruiting | N/A | 1000 | RoW | BuMA Supreme | Sino Medical Sciences Technology Inc. | Coronary Artery Disease | 05/19 | 12/25 | | |
| Recruiting | N/A | 4500 | RoW | | Harbin Medical University, Abbott | Acute Myocardial Infarction | 07/21 | 12/22 | | |
SIBLINT ISR, NCT04240444: Sirolimus-Coated Balloon Versus Paclitaxel-Coated Balloon for the Treatment of Coronary In-Stent Restenosis |
|
|
| Completed | N/A | 260 | RoW | drug-coated balloon Catheter | B. Braun Medical International Trading Company Ltd., CCRF Inc., Beijing, China | Coronary Artery Disease, In Stent Restenosis | 07/22 | 08/22 | | |
| Not yet recruiting | N/A | 220 | RoW | Paclitaxel-Eluting Coronary Balloon Dilation Catheter (DIOR), Paclitaxel-Eluting Balloon (Bingo) | CCRF Inc., Beijing, China | Percutaneous Coronary Intervention | 05/22 | 10/22 | | |
NCT04953117: A Safety and Efficacy Study of Lepu® Drug Coated Balloon in Treatment of Coronary Small-vessel Disease |
|
|
| Recruiting | N/A | 286 | RoW | DCB of Lepu Medical(dimeter≥2.00 mm), Coronary Drug Coated Balloon Catheter of Lepu Medical for coronary small vessels, Restore DEB, RESTORE Paclitaxel releasing coronary balloon catheter, DCB of Lepu Medical(dimeter<2.00 mm), Coronary Drug Coated Balloon Catheter of Lepu Medical for coronary very small vessels | Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Artery Disease | 06/22 | 04/23 | | |
REAL, NCT05970159: Impact of Preoperative Serum Albumin Level on Postoperative Outcomes in Chinese HCC Patients Treated With Surgery |
|
|
| Recruiting | N/A | 480 | RoW | | Shanghai Zhongshan Hospital, Takeda | Hepatocellular Carcinoma | 06/24 | 03/25 | | |
NCT05755776: The Efficacy and Safety of Tenofovir Amibufenamide to Treat Low-level Viraemia After Entecavir Treatment |
|
|
| Recruiting | N/A | 204 | RoW | TMF, Heng Mu | The Second Affiliated Hospital of Chongqing Medical University, Jiangsu Hansoh Pharmaceutical Co., Ltd. | Chronic Hepatitis B | 12/24 | 12/24 | | |
| Li, Yi |
NCT05058040: A Clinical Study to Evaluate the Long-Term Safety Sodium Oligomannate Capsules (GV-971) |
|
|
| Active, not recruiting | 4 | 2500 | RoW | Sodium Oligomannate Capsules | Green Valley (Shanghai) Pharmaceuticals Co., Ltd. | Alzheimer Disease | 04/24 | 04/25 | | |
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD) |
|
|
| Active, not recruiting | 4 | 8250 | RoW | Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy | Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases | 04/25 | 04/25 | | |
NCT05908695: An Efficacy and Safety Study of Sodium Oligomannate (GV-971) for the Treatment of Alzheimer's Disease |
|
|
| Recruiting | 4 | 1312 | RoW | GV-971, Placebo | Green Valley (Shanghai) Pharmaceuticals Co., Ltd. | Alzheimer's Disease | 06/29 | 12/29 | | |
NCT03236636: The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma Subjects |
|
|
| Recruiting | 3 | 312 | RoW | Icaritin, SNG-162, HUACHANSU PIAN, HUACHANSU PIAN（999） | Beijing Shenogen Biomedical Co., Ltd, Chinese Academy of Medical Sciences, NanJing PLA 81 Hospital, Peking University Cancer Hospital & Institute, Beijing Hospital, Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Jinan Central Hospital, Linyi Tumour Hospital, The First Affiliated Hospital of Anhui Medical University, Anhui Provincial Hospital, The First Affiliated Hospital with Nanjing Medical University, The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China, Nanfang Hospital of Southern Medical University, First People's Hospital of Foshan, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Hebei Medical University Fourth Hospital, The First Hospital of Jilin University, Haikou People's Hospital, Fudan University, West China Hospital, Chongqing Traditional Chinese Medicine Hospital, Chifeng Municipal Hospital, The Affiliated Hospital of Hangzhou Normal University, The First Affiliated Hospital of Zhengzhou University, Guilin Medical University, China, The Third Xiangya Hospital of Central South University, Yunnan Provincial Hospital of Traditional Chinese Medicine, The Sixth People's Hospital of Shenyang | Advanced HBV-Related Hepatocellular Carcinoma (HCC) | 12/22 | 12/22 | | |
| Recruiting | 3 | 700 | Europe, Canada, US, RoW | Troriluzole, Placebo | Biohaven Pharmaceuticals, Inc. | Obsessive-Compulsive Disorder | 04/25 | 04/25 | | |
| Zhang, Yong |
HER2CLIMB-02, NCT03975647: A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer |
|
|
| Recruiting | 3 | 565 | Europe, Canada, Japan, US, RoW | tucatinib, ONT-380, placebo, T-DM1, Kadcyla | Seagen Inc. | HER2-positive Breast Cancer | 06/23 | 10/27 | | |
|
|
| Recruiting | 3 | 650 | Europe, Canada, Japan, US, RoW | Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo | Seagen Inc., Merck Sharp & Dohme LLC | HER2 Positive Breast Cancer | 10/24 | 06/27 | | |
NCT05719688: Evaluate the Safety and Efficacy of Thrombectomy System in the Intravascular Treatment of Acute Ischemic Stroke |
|
|
| Recruiting | N/A | 200 | RoW | Mechanical thrombectomy | Suzhou Hengruihongyuan Medical Technology Co. LTD | Acute Ischemic Stroke | 12/23 | 12/24 | | |
NCT06365697: Evaluation of the Ton-bridge Carotid Stent for Carotid Artery Stenosis |
|
|
| Not yet recruiting | N/A | 188 | RoW | Ton-bridge carotid stent, WALLSTENT carotid stent | Zhuhai Tonbridge Medical Tech. Co., Ltd. | Carotid Artery Stenosis | 11/24 | 10/25 | | |
| Zhang, Yu |
NCT04683406: A Study of ZSP1273 Tablets in Patients With Acute Uncomplicated Influenza A |
|
|
| Completed | 3 | 750 | RoW | ZSP1273 600 mg, Placebo to Oseltamivir, Oseltamivir(oral), Placebo to ZSP1273 | Guangdong Raynovent Biotech Co., Ltd | Influenza A | 04/23 | 05/23 | | |
NCT06300177: D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure |
|
|
| Recruiting | 3 | 522 | RoW | D-1553 Tablet, Docetaxel injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non Small Cell Lung Cancer | 10/26 | 12/27 | | |
| Active, not recruiting | 3 | 90 | Europe, Canada, US, RoW | Pimicotinib(ABSK021), Placebo | Abbisko Therapeutics Co, Ltd | Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath | 05/26 | 06/28 | | |
NCT04924192: A Clinical Study of TQB3616 Capsules Combined With Anlotinib Hydrochloride Capsules or Standard Chemotherapy Second-line and Above in the Treatment of Advanced Lung Cancer |
|
|
| Recruiting | 2 | 126 | RoW | TQB3616 capsules, Anlotinib Hydrochloride capsules, Irinotecan Hydrochloride for Injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Lung Carcinoma | 05/23 | 12/23 | | |
NCT05148195: A Phase II Study of Envofolimab and BD0801 With/Without Chemotherapy in Patients With Advanced Solid Tumors |
|
|
| Terminated | 2 | 86 | RoW | Envofolimab, BD0801, Docetaxel, Irinotecan, Leucovorin calcium, 5-Fluorouridine | Jiangsu Simcere Pharmaceutical Co., Ltd. | Advanced Solid Tumor | 07/23 | 07/23 | | |
NCT06251947: Efbemalenograstim Alfa Injection for Ovarian or Cervical Cancer Receiving Chemotherapy Regimen |
|
|
| Recruiting | 2 | 83 | RoW | Efbemalenograstim Alfa | Shandong University, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Ovarian Cancer, Cervical Cancer | 06/26 | 12/26 | | |
NCT06434610: A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer. |
|
|
| Not yet recruiting | 2 | 90 | RoW | B013, Paclitaxel, Placebo | Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd | Platinum-resistant Recurrent Ovarian Cancer | 12/26 | 12/26 | | |
NCT06014190: HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer |
|
|
| Recruiting | 2 | 460 | RoW | HS-20089 | Hansoh BioMedical R&D Company | Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial Cancer | 12/25 | 12/27 | | |
NCT06118788: Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia |
|
|
| Recruiting | 1/2 | 24 | RoW | BG1805 | Guangzhou Bio-gene Technology Co., Ltd | Leukemia, Myeloid, Acute | 03/25 | 07/25 | | |
NCT05416775: Phase Ib/II Study of SHR-8068 Injection in the Treatment of Advanced Non-small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 168 | RoW | SHR-8068；Adebrelimab, SHR-8068；adebrelimab and platinum-based chemotherapy, Adebrelimab；platinum-based chemotherapy | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Advanced Non-small Cell Lung Cancer | 06/26 | 06/26 | | |
NCT05788159: An Open Label, Balanced, Randomized, Two-Treatment, Two-Period, Two-Sequence, Two-way Crossover, Oralcomparative Pharmacokinetic（PK）Study of Lacosamide Extended-Release Tablets , Adult, Human Subjects Under Fasting Conditions. |
|
|
| Not yet recruiting | 1 | 16 | RoW | Lacosamide Tablets, Lacosamide extended release tablets | Overseas Pharmaceuticals, Ltd., Beijing Capton Pharmaceutical Technology Development Co., LTD | Epilepsy | 06/23 | 07/23 | | |
NCT06387082: A Clinical Study of HMPL-506 in Patients With Hematological Malignancies |
|
|
| Recruiting | 1 | 98 | RoW | HMPL-506, Two strengths of HMPL-506 tablets (25 mg and 100 mg) will be used for this clinical study | Hutchmed | Hematological Malignancies | 10/27 | 12/27 | | |
NCT06412458: IM83 Clinical Study of CAR-T Cell Therapy in Patients With Relapsed or Refractory Osteosarcoma |
|
|
| Not yet recruiting | 1 | 9 | RoW | IM83 CAR-T Cells | Beijing Immunochina Medical Science & Technology Co., Ltd., Guangdong Provincial People's Hospital | Refractory Osteosarcoma, Recurrent Osteosarcoma | 06/25 | 06/26 | | |
APG-115-AC101, NCT04275518: A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS. |
|
|
| Recruiting | 1 | 102 | RoW | APG-115, Azacitidine, Cytarabine | Ascentage Pharma Group Inc., Suzhou Yasheng Pharmaceutical Co., Ltd. | Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) | 12/25 | 12/25 | | |
| Xu, Fei |
public, NCT06162286: A Phase 3b Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of Omadacycline to Moxifloxacin for Treating Adult Subjects With CABP |
|
|
| Recruiting | 3 | 100 | RoW | Omadacycline, Moxifloxacin | Zai Lab (Hong Kong), Ltd. | Community-acquired Bacterial Pneumonia | 01/25 | 11/25 | | |
NCT05042375: A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 450 | RoW | camrelizumab + famitinib, pembrolizumab, camrelizumab | Jiangsu HengRui Medicine Co., Ltd. | Non-small Cell Lung Cancer | 12/23 | 12/25 | | |
| Active, not recruiting | 3 | 806 | Europe, Canada, Japan, US, RoW | Placebo, Mepolizumab | GlaxoSmithKline, PPD | Pulmonary Disease, Chronic Obstructive | 08/24 | 08/24 | | |
|
|
|
|
|
FOCUS-C, NCT05334277: Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA |
|
|
| Recruiting | 2 | 280 | RoW | Furmonertinib, AST2818, Furmonertinib/Pemetrexed/Carboplatin, Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab | Sun Yat-sen University, Allist Pharmaceuticals, Inc., GeneCast Biotechnology Co., Ltd. | Non-small Cell Lung Cancer | 02/25 | 02/28 | | |
NCT05956587: A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors |
|
|
| Recruiting | 2 | 121 | RoW | BL-B01D1, SI-B003 | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma | 11/25 | 11/25 | | |
NCT06107049: the Effect of Probiotic on Sleep Quality Management |
|
|
| Completed | N/A | 110 | RoW | BLa80 | Wecare Probiotics Co., Ltd. | Poor Quality Sleep | 03/24 | 03/24 | | |
| Not yet recruiting | N/A | 120 | NA | Probiotic BBr60 | Wecare Probiotics Co., Ltd. | Alcohol Drinking, Adult Disease | 07/24 | 08/24 | | |
| Li |
| Recruiting | 3 | 41 | Europe, Canada, Japan, US, RoW | Emapalumab, NI-0501, emapalumab-lzsg, ATC code: L04AA39 (WHO) | Swedish Orphan Biovitrum | Macrophage Activation Syndrome, Secondary Hemophagocytic Lymphohistiocytosis, Still Disease, Systemic Lupus Erythematosus, SJIA, AOSD, MAS | 09/24 | 09/25 | | |
NCT05668988: A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28) |
|
|
| Recruiting | 3 | 320 | Europe, Canada, US, RoW | DZD9008, Pemetrexed+carboplatin | Dizal Pharmaceuticals | Non-small Cell Lung Cancer | 02/26 | 10/27 | | |
JACKPOT8, NCT04105010: Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL |
|
|
| Completed | 2 | 171 | US, RoW | AZD4205 | Dizal Pharmaceuticals | Relapsed or Refractory Peripheral T Cell Lymphoma | 10/23 | 02/24 | | |
NCT04614740: The Phase I/Phase II Clinical Study of VC004 in Patients With Localized Advanced/Metastatic Solid Tumors |
|
|
| Recruiting | 2 | 115 | RoW | VC004 | Jiangsu vcare pharmaceutical technology co., LTD | Locally Advanced Solid Tumor, Metastatic Solid Tumor | 01/24 | 06/24 | | |
NCT06175351: Study to Evaluate the Pharmacokinetic Characteristics, Safety, Tolerability, and Preliminary Efficacy of 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD). |
|
|
| Recruiting | 1/2 | 80 | RoW | 9MW1911, Placebo | Mabwell (Shanghai) Bioscience Co., Ltd. | Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) | 09/25 | 09/25 | | |
NCT05508100: Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors |
|
|
| Completed | 1 | 38 | RoW | IO-108, IO-108 + pembrolizumab, IO-108 + Keytruda®, IO-108 + tislelizumab | Immune-Onc Therapeutics | Advanced Solid Tumor | 04/24 | 04/24 | | |
NCT06020690: A Clinical Study to Evaluate the Safety and Effectiveness of Novabel Bioabsorbable Steroid-releasing Stent for the Chronic Sinusitis |
|
|
| Recruiting | N/A | 93 | RoW | bioabsorbable steroid-releasing stent, functional endoscopic sinus surgery | Enlight Medical Technologies (Shanghai) Co., Ltd | Chronic Sinusitis | 09/24 | 09/25 | | |
| ma, xiangyu |
NCT05170958: A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors |
|
|
| Recruiting | 1/2 | 396 | RoW | LBL-024 for Injection, LBL-024 | Nanjing Leads Biolabs Co.,Ltd | Advanced Solid Tumor | 12/26 | 12/26 | | |
| Recruiting | 1/2 | 490 | RoW | LBL-007 Injection, LBL-007, Tislelizumab Injection, Tislelizumab, Cisplatin Injection, Cisplatin, Gemcitabine Hydrochloride for Injection, Gemcitabine Hydrochloride, Docetaxel injection, Docetaxel | Nanjing Leads Biolabs Co.,Ltd | Malignant Tumors | 10/24 | 06/25 | | |
NCT04640545: A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma |
|
|
| Recruiting | 1 | 88 | RoW | LBL-007, Toripalimab, Axitinib Tablets | Nanjing Leads Biolabs Co.,Ltd | Advanced Melanoma | 08/24 | 12/24 | | |
| Tang, Yufeng |
| Recruiting | 3 | 248 | RoW | pimavanserin tartrate, placebo | Tasly Pharmaceutical Group Co., Ltd | Parkinson's Disease Psychosis | 06/25 | 01/26 | | |
| Ren, Peirong |
NCT05042375: A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 450 | RoW | camrelizumab + famitinib, pembrolizumab, camrelizumab | Jiangsu HengRui Medicine Co., Ltd. | Non-small Cell Lung Cancer | 12/23 | 12/25 | | |
NCT06300177: D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure |
|
|
| Recruiting | 3 | 522 | RoW | D-1553 Tablet, Docetaxel injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non Small Cell Lung Cancer | 10/26 | 12/27 | | |
